• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Exercise Science >The Effects of PCSO-524?, a Patented Marine Oil Lipid derived from the New Zealand Green Lipped Mussel (Perna canaliculus), on Pulmonary and Respiratory Muscle Function in Non-asthmatic Elite Runners
【24h】

The Effects of PCSO-524?, a Patented Marine Oil Lipid derived from the New Zealand Green Lipped Mussel (Perna canaliculus), on Pulmonary and Respiratory Muscle Function in Non-asthmatic Elite Runners

机译：PCSO-524？（一种来自新西兰绿色唇贻贝（Perna canaliculus）的专利海洋油脂）对非哮喘精英跑步者肺和呼吸肌功能的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

International Journal of Exercise Science 11(3): 669-680, 2018. Habitual endurance training may be associated with mild airway inflammation and subsequent deterioration in lung function. PCSO-524? (Lyprinol?/Omega-XL?), a supplement extracted from the New Zealand green-lipped mussel (Perna canaliculus), has been shown to moderate airway inflammation in asthmatic subjects. The purpose of this study was to determine whether supplementation with PCSO-524? improves pulmonary and respiratory muscle function in non-asthmatic elite runners. Sixteen male, non-asthmatic elite runners were randomly assigned to either a treatment (PCSO-524?; 1 capsule contains 50 mg n-3 polyunsaturated fatty acids and 100 mg olive oil, n=8) or placebo (1 capsule contains 150 mg olive oil; n=8) group. During the supplementation period, subjects ingested 8 capsules of either treatment or placebo per day for 12 weeks. Resting pulmonary and respiratory muscle function testing were assessed at baseline and every two weeks throughout the 12 week supplementation period. No significant between- or within-subjects main effects were observed in forced vital capacity, forced expiratory volume in 1-second, forced expiratory flow from 25-75% of lung volume (FEF25-75), peak expiratory flow, maximal voluntary ventilation, maximal inspiratory mouth pressure, and closing volume (p>0.05). A significant within-subjects main effect was observed in maximal expiratory mouth pressure (PEmax) (p=0.024) and lung diffusion capacity (DLCO) (pPEmax and DLCO (p>0.05). A significant treatment by time interaction was observed in FEF25-75 (p=0.026) and DLCO (p=0.024), but no other significant interactions were observed (all p>0.05). Supplementation with PCSO-524? (Lyprinol?/Omega-XL?) does not improve pulmonary or respiratory muscle function in non-asthmatic elite runners.
机译：国际运动科学杂志11（3）：669-680，2018.习惯耐力训练可能与轻度气道炎症和随后肺功能恶化有关。 PCSO-524？从新西兰绿唇贻贝（Perna canaliculus）中提取的一种补充剂（Lyprinol？/ Omega-XL？）已被证明可缓解哮喘患者的气道炎症。这项研究的目的是确定是否补充PCSO-524？改善非哮喘精英跑步者的肺和呼吸肌功能。随机将16名男性非哮喘精英跑步者分配到一种治疗方法（PCSO-524？; 1胶囊含有50 mg n-3多不饱和脂肪酸和100 mg橄榄油，n = 8）或安慰剂（1胶囊含有150 mg橄榄油; n = 8）组。在补充期间，受试者每天摄入8粒治疗药或安慰剂胶囊，持续12周。在补充治疗的12周期间，在基线和每两周评估一次静息的肺和呼吸肌功能测试。在强制肺活量，1秒内强制呼气量，肺容积的25％至75％的强制呼气流量（FEF25-75），呼气流量峰值，最大自愿通气，最大吸气口压力和闭合容积（p> 0.05）。在受试者最大呼气口压力（PEmax）（p = 0.024）和肺弥散能力（DLCO）（pPEmax和DLCO（p> 0.05）方面，观察到了显着的受试者内主要作用;在FEF25- 75（p = 0.026）和DLCO（p = 0.024），但未观察到其他显着相互作用（所有p> 0.05），补充PCSO-524？（Lyprinol？/ Omega-XL？）不能改善肺或呼吸肌在非哮喘病精英运动员中发挥作用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号